Anavex Life Sciences Corp to Discuss the Top-line Results from the Phase 3 AVATAR Clinical Trial of ANAVEX(®)2-73 Transcript
Good morning, and welcome, everyone. Welcome to the Anavex Life Sciences AVATAR ANAVEX 2-73 Phase III Top Line Data Conference Call. My name is Clint Tomlinson, and I'll be your host for today's call. (Operator Instructions) Please note, this conference is being recorded. The call will be available for replay on Anavex's website at www.anavex.com.
With us today is Dr. Christopher Missling, President and Chief Executive Officer; and Dr. Ed Hammond, Chief Medical Officer; and Walter E. Kaufmann, Chief Scientific Officer.
Before we begin, please note that during this conference call, the company will make some projections and forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. We encourage you to review the company filings with the SEC. This includes, without limitation, the company's Forms 10-K and 10-Q, which identify specific factors that may cause actual
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
